These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy. Christopher M, Hew FL, Oakley M, Rantzau C, Alford F. J Clin Endocrinol Metab; 1998 May; 83(5):1668-81. PubMed ID: 9589675 [Abstract] [Full Text] [Related]
5. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Resmini E, Minuto F, Colao A, Ferone D. Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513 [Abstract] [Full Text] [Related]
6. Persisting effects on fasting glucose levels and insulin sensitivity after 6 months of discontinuation of a very low-dose GH therapy in adults with severe GH deficiency. Yuen KC, Dunger DB. Clin Endocrinol (Oxf); 2006 May; 64(5):549-55. PubMed ID: 16649975 [Abstract] [Full Text] [Related]
12. The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ, Murphy LJ. Clin Endocrinol (Oxf); 2004 Apr; 60(4):442-50. PubMed ID: 15049958 [Abstract] [Full Text] [Related]
13. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J, Froesch ER. J Clin Invest; 1994 Sep; 94(3):1126-33. PubMed ID: 8083353 [Abstract] [Full Text] [Related]